Coach vs. Kors: Bat...
Health Care: Drugs
Discovery Laboratories Inc. (DSCO: NASDAQ)
$2.50 -0.02 | -0.79%
06/04/12 - 09:34 AM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 582.00K | 0.00 | 0.00 | 4.60M |
| Cost of Sales | -1.23M | -1.55M | -1.99M | -2.22M |
| Gross Operating Profit | 1.82M | 1.55M | 1.99M | 6.82M |
| Selling, General, and Administrative Expenses | 7.86M | 8.39M | 10.12M | 16.43M |
| Research & Development | 17.23M | 17.14M | 19.08M | 26.57M |
| Operating Income before D & A (EBITDA) | -23.28M | -23.98M | -27.20M | -36.18M |
| Depreciation & Amortization | 1.23M | 1.55M | 1.99M | 2.22M |
| Interest Income | 13.00K | 288.00K | 39.00K | 902.00K |
| Other Income - Net | 3.56M | 6.42M | 0.00 | 0.00 |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -20.94M | -18.82M | -29.16M | -37.49M |
| Interest Expense | 26.00K | 357.00K | 1.08M | 1.61M |
| Pre-Tax Income | -20.96M | -19.18M | -30.24M | -39.11M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -20.96M | -19.18M | -30.24M | -39.11M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -20.96M | -19.18M | -30.24M | -39.11M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -20.96M | -19.18M | -30.24M | -39.11M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-20.96M | -19.18M | -30.24M | -39.11M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -20.96M | -19.18M | -30.24M | -39.11M |
| Basic EPS from Continuing Ops. | -0.93 | -1.65 | -3.90 | -6.00 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.93 | -1.65 | -3.90 | -6.00 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.93 | -1.65 | -3.90 | -6.00 |
| Basic Normalized Net Income/Share | -0.93 | -1.65 | -3.90 | -6.00 |
| EPS fr Continuing Ops. | -0.93 | -1.65 | -3.90 | -6.00 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.93 | -1.65 | -3.90 | -6.00 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.93 | -1.65 | -3.90 | -6.00 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.93 | -1.65 | -3.90 | -6.00 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with DSCO
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- UserSmall Cap Stocks
- UserKJP Spring Break
- Userjet189 Portfolio 1
- Uservolume spike
- Usermoon_in_mood Portfolio 1
- UserDtech Portfolio 1
- UserLizann
- UserBNunnally Portfolio 1
- Usershaldar Portfolio 1
Latest DSCO Headlines from TheStreet
- 5 Stocks Under $10 Poised for Upside 04.27.12 | 11:04 am
- For Biotech Takeovers, Timing is Key 04.04.12 | 06:04 am
- For Biotech, 'Fail' is Making a Big Comeback 03.12.12 | 08:03 am
- Biotech Stock Mailbag: Oncothyreon, Amag, Keryx Hate Mail 03.09.12 | 05:03 am
- Market Preview: The Bulls Finally Blink (Correct) 03.06.12 | 10:03 pm
- Pandora, Discovery Labs: After-Hours Trading (Update 1) 03.06.12 | 08:03 pm
- The Next Big Thing in Biotech: Discovery Labs
03.02.12 | 06:03 am - Biotech Stock Mailbag: Cyclacel Fallout, the Skinny on Vivus, Celldex's Crash 03.02.12 | 05:03 am
- These Drugs Stocks Will Win FDA Approval 02.16.12 | 12:02 pm
- Play TheStreet's FDA Drug-Approval Contest 01.23.12 | 08:01 am
Press Releases for DSCO
- Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated With Reintubation In Premature Infants - PR Newswire 05.01.12 | 07:05 am
- Media Alert: Discovery Labs To Hold Conference Call To Discuss FDA Approval Of SURFAXIN® (lucinactant) - PR Newswire 03.07.12 | 07:03 am
- Discovery Labs Announces FDA Approval Of SURFAXIN® (lucinactant) For Prevention Of Respiratory Distress Syndrome - PR Newswire 03.06.12 | 04:03 pm
- Discovery Labs Signs Manufacturing Agreement For AFECTAIR® - PR Newswire 02.08.12 | 07:02 am
- Discovery Labs Cleared To Market AFECTAIR In U.S. - PR Newswire 02.02.12 | 07:02 am
- New Study Shows AFECTAIR® Significantly Improved Delivery Of Nitric Oxide Under Simulated Neonatal Ventilatory Conditions - PR Newswire 12.06.11 | 08:12 am
- Discovery Labs Releases New AFECTAIR⢠Performance Data Presented At The American Association For Respiratory Care Annual Meeting - PR Newswire 11.08.11 | 08:11 am
- New Study Shows Neonatologists And Parents Of NICU Infants Share Concern Regarding Newborn Exposure To Animal-Derived Medications - PR Newswire 10.18.11 | 07:10 am
- Discovery Labs Notified Of PDUFA Date For SURFAXIN® - PR Newswire 09.28.11 | 12:09 pm
- Discovery Labs Submits SURFAXIN® Complete Response To FDA - PR Newswire 09.06.11 | 07:09 am
Partner Headlines for DSCO
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Bio-Pharma Drug Approval Watch List: Final Results Plus One To Watch - Seeking Alpha 03.30.12 | 09:03 am
- Discovery Labs Down 17% After Public Offering Announcement - Benzinga 03.16.12 | 09:03 am
- Company News for March 8, 2012 - Corporate Summary - Zacks 03.08.12 | 10:03 am
- Discovery Labs Up 33% After Surfaxin Approved by the FDA - Benzinga 03.07.12 | 09:03 am
- Discovery Labs Announces FDA Approval of SURFAXIN for Prevention of Respiratory Distress Syndrome - Benzinga 03.06.12 | 04:03 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 11.15.11 | 09:11 am
- UPDATE 1-Discovery Labs' cystic fibrosis drug gets orphan status - Reuters 11.01.10 | 08:11 am
- UPDATE 1-Discovery Labs lung drug disappoints in mid-stage trial - Reuters 06.09.10 | 08:06 am
- FDA, Clinical Trial News: Discovery Labs, Hospira, Javelin Pharma - Seeking Alpha 05.20.10 | 06:05 am
